###### Strengths and limitations of this study

-   A comprehensive review conducted using methods outlined by Cochrane Collaboration including Grading of Recommendations Assessment Development and Evaluation to assess risk of bias and evidence certainty.

-   Inclusion of a broad range of interventions, including behavioural to improve sun protection behaviour and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence.

-   Difficulty obtaining an overall summary estimate for many outcomes due to the variability in the analytical methods and reporting in individual studies.

-   Unable to perform detailed subgroup analyses or assess for publication bias due to small number of studies.

-   Few trials included the important outcomes of skin cancer and none included melanoma or mortality.

Introduction {#s1}
============

Skin cancer, including melanoma and non-melanoma skin cancer (NMSC), is the most frequently diagnosed malignancy among solid organ transplant recipients, affecting more than 50% of post-transplantation recipients.[@R1] The cumulative incidence of NMSC increases with time after transplantation, from 5%--10% at 2 years to 40%--80% at 20 years.[@R2] Compared with the general population, there is a higher rate of squamous cell carcinoma (SCC) to basal cell carcinoma (BCC), with an incidence of 65 to 250 times greater than the age and gender-matched general population.[@R5] Once cancer develops, management options are limited as immunotherapy may be unsuitable as it may lead to graft rejection.[@R9] Although registry data show improvement in survival rates of transplant recipients as a result of improved transplantation techniques and management of immunosuppression, there is a greater burden of skin cancer and cancer-related mortality.[@R11] The excess risk of death from invasive and metastatic skin cancer, such as SCC and melanoma, are three to nine times higher than the general population, with 5-year overall survival of \<30%.[@R6]

Sun exposure behaviours remain the most significant and modifiable risk factor in the prevention of skin cancers in the general population.[@R16] However, with the dramatic increase in skin cancers in solid organ transplant recipients, pharmaceuticals have also been used to reduce and delay the development of skin cancer.[@R16] Current recommendations for preventive strategies have often been extrapolated from guidelines in the general population, which may not be applicable to solid organ transplant recipients.[@R18] For example, frequent skin self-examination and annual to biannual total body skin examination are generally recommended for the general population.[@R18] Sun protective behaviours including use of sunscreen, protective clothing and limiting sun exposure during peak hours of high UV index days are potential measures for skin cancer prevention.[@R3] Further, alteration of maintenance immunosuppression such as conversion to mammalian target of rapamaycin inhibitors (mTORis) and secondary prevention using retinoid acitretin are recommended for management of skin cancers in high-risk transplant recipients.[@R20]

The aim of this study is determine the effectiveness of interventions that promote behavioural change and skin cancer prevention in solid organ transplant recipients.

Methods {#s2}
=======

This systematic review followed a prespecified protocol registered in PROSPERO (CRD42017063962) and is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses checklist.[@R21]The study was exempt from approval from an ethics' board.

Inclusion criteria {#s2-1}
------------------

All randomised controlled trials (RCTs) or quasi RCTs (allocated to trial arms by investigators) of interventions for skin cancer prevention (both melanoma and NMSC) in solid organ transplant recipients were included. Behavioural interventions defined as any strategy used to promote sun protective behaviour including passive (eg, pamphlets), active (eg, group workshops, counselling, dermatology clinic) and provision of sun protective equipment; and pharmaceutical interventions (switch to mTORis, photodynamic therapy, immune response modifiers, nicotinamide and oral retinoids) and studies that reported skin cancer-related outcomes as their primary outcomes were included. Studies that did not report these outcomes as primary endpoints were excluded. Studies of interventions for the treatment of skin cancer were excluded.

Search strategies {#s2-2}
-----------------

We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL from inception to November 2019 without language restriction, using search strategies designed by a specialist information manager (see Medline search strategy in [online supplementary figure S1](#SP1){ref-type="supplementary-material"}). Reference lists of included studies were also searched.
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Data extraction {#s2-3}
---------------

Titles and abstracts were reviewed by two independent authors (LJJ and LDWL) and those who did not meet the inclusion criteria were excluded. Full-text articles were reviewed by three independent reviewers (LJJ, VS, LDWL) and any disagreements were resolved by discussion. Data on study design, geographic location, sample size, type of transplant, measurement of interventions, interventions and comparators were extracted. We sought unclear or missing information from authors where possible.

Outcome measures {#s2-4}
----------------

The prespecified outcome measures were incidence of precancerous and cancerous lesions, sun protection behaviour (including use of sunscreen, use of protective clothing including hats and sunglasses, shade and sun avoidance), knowledge and attitude, skin self-examination, sun exposure (including skin irritation, sunburn) and biologic measures (including measurement of melanin index and sun damage assessment).

Risk of bias and quality of evidence {#s2-5}
------------------------------------

The risk of bias was assessed independently by LJJ and VS using the Cochrane risk of bias tool.[@R22] The domains included in the assessment were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, trial registration and industry involvement. Each criterion was assigned a judgement of high, low or unclear risk of bias. Intention to treat and lost to follow-up were also assessed for each study. The quality of the evidence informing summary estimates for each outcome was then assessed by LJJ using the Grading of Recommendations Assessment Development and Evaluation (GRADE) guidelines.[@R23]

Data synthesis and statistical analyses {#s2-6}
---------------------------------------

Continuous outcomes were summarised as mean difference (MD) or standardised mean difference (SMD) and dichotomous outcomes as relative risk (RR). A MD/SMD greater than 0 and/or a RR greater than 1 could be interpreted as favouring the intervention group relative to the control, unless specified elsewhere. Risk estimates were reported with 95% CIs, using random effects meta-analysis. We quantified the heterogeneity using the I² statistic. An I^2^ value of \<25% was considered to represent low heterogeneity and \>75% as high heterogeneity. When sufficient data were available, possible sources of heterogeneity were investigated using subgroup analysis based on prespecified study characteristics including sample size, trial duration, setting and overall risk of bias. Funnel plots were planned to evaluate small study effects when at least 10 studies were included in meta-analysis. All analyses were conducted using Review Manager V.5.3 software.

Patient and public involvement {#s2-7}
------------------------------

There was no patient or public involvement.

Results {#s3}
=======

Study selection {#s3-1}
---------------

The literature search identified 1280 articles, of which, 1201 were excluded after abstract and title review. Full-text assessment of 79 studies found 22 eligible articles for inclusion ([figure 1](#F1){ref-type="fig"}).

![Study selection. RCT, randomised controlled trial.](bmjopen-2019-029265f01){#F1}

Studies characteristics {#s3-2}
-----------------------

We included 22 reports of 20 RCTs, including 2295 participants ([figure 1](#F1){ref-type="fig"}). The study characteristics are summarised in [tables 1 and 2](#T1 T2){ref-type="table"}. The median number of participants was 44 (range 17--830) and the median follow-up duration was 10 months (range 1 day to 60 months). All studies included kidney transplant recipients, with some also including heart transplant recipients (n=1), liver, heart, pancreas, lung, heart/lung and other transplants (n=1), and lung and liver transplant recipients (n=2). In total, 15 (76%) of 21 studies provided sufficient data for the meta-analyses. Six studies did not meet final criteria for meta-analysis as they had the same sample of participants (n=1),[@R24] or did not provide data that were able to be meta-analysed (n=5).[@R25]

###### 

Characteristics of included studies (n=20)

  Characteristics                     N (%)
  ----------------------------------- ---------
  Type of transplant                  
   Kidney                             16 (80)
   Multiple\*                         4 (20)
  Sex                                 
   ≥50% Male                          18 (90)
   \<50% Male                         1 (5)
   Not specified                      1 (5)
  Age (mean)                          
   \<60                               10 (50)
   ≥60                                5 (25)
   Not specified                      5 (25)
  Sample size                         
   10--50                             11 (55)
   50--100                            3 (15)
   100--200                           4 (20)
   \>200                              2 (10)
  Setting                             
   Single centre                      8 (40)
   Multicentre                        11 (55)
   Not specified                      1 (5)
  Country of origin                   
   Australia                          3 (15)
   Denmark                            4 (20)
   France                             1 (5)
   Germany                            1 (5)
   Netherlands                        2 (10)
   New Zealand                        2 (10)
   Switzerland                        1 (5)
   Sweden                             1 (5)
   UK                                 3 (15)
   USA                                6 (30)
   Other†                             1 (5)
  Intervention type                   
   Behavioural                        5 (25)
   Switch to mTORis                   6 (30)
   Photodynamic therapy               4 (20)
   Oral retinoid                      3 (15)
   Nictotinamide                      1 (5)
   Topical immune response modifier   1 (5)
  Duration of follow-up               
   \<12 months                        9 (45)
   12 months                          4 (20)
   24 months                          5 (25)
   \>24 months                        1 (5)
   Not specified                      1 (5)
  Year of publication                 
   1995--1999                         1 (5)
   2000--2004                         3 (15)
   2005--2009                         4 (20)
   2010--2014                         8 (40)
   2015--2017                         4 (20)

\*Kidney, liver and lung (n=2); kidney and heart (n=1); kidney and multiple other types (n=1)---see text.

†111 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, USA), South Africa and South America (Argentina, Brazil, Chile).

mTORis, mammalian target of rapamaycin inhibitors.

###### 

Characteristics of individual studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                                                                N     Type of transplant                                         Setting                                    Type of intervention                     Measures                                                           Intervention                               Comparator                        Primary outcomes                                 Time (months)
  ------------------------------------------------------------------------------------------------------------------------------------ ----- ---------------------------------------------------------- ------------------------------------------ ---------------------------------------- ------------------------------------------------------------------ ------------------------------------------ --------------------------------- ------------------------------------------------ ---------------
  **Behavioural interventions (n=6)**                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Clowers-Webb 2006[@R30]                                                                                                              202   Kidney, liver, heart, pancreas, lung, heart/lung, other§   Single centre, USA                         Behavioural                              Self-reported questionnaire                                        Repetitive written material                Standard care                     Knowledge and behaviour                          10

  Robinson 2011[@R33]                                                                                                                  75    Kidney                                                     USA                                        Behavioural                              Self-reported questionnaire                                        Workbook                                   Standard care                     Knowledge and behaviour                          1

  Robinson 2014[@R31]                                                                                                                  101   Kidney                                                     Single centre, USA                         Behavioural                              Self-reported questionnaire Physical examination                   Workbook Text messages                     Standard care                     Knowledge and behaviour                          1.5

  Robinson 2015[@R24] ‡                                                                                                                170   Kidney                                                     Multicentre, USA                           Behavioural                              Self-reported questionnaire                                        Mobile app program                         Standard care                     Knowledge and behaviour                          0.5

  Robinson 2016[@R32]                                                                                                                  170   Kidney                                                     Multicentre, USA                           Behavioural                              Self-reported questionnaire Physical examination                   Mobile app program                         Standard care                     Knowledge and behaviour                          1.5

  Trinh 2014[@R28] \*                                                                                                                  100   Kidney, liver, lung                                        Single centre, USA                         Behavioural                              Self-reported questionnaire                                        Video                                      Pamphlet                          Knowledge                                        1 day

  **Switch to mTORis (n=7)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Alberu 2011[@R39]                                                                                                                    830   Kidney                                                     Multicentre§                               Switch to mTORis                         Investigator-reported adverse events                               Conversion to sirolimus                    CNI                               Cancer incidence                                 24

  Campbell 2012[@R41]                                                                                                                  86    Kidney                                                     Multicentre, Australia, New Zealand, USA   Switch to mTORis                         Physical examination +/− biopsy                                    Conversion to sirolimus                    CNI                               Cancer incidence                                 12

  Carroll 2013[@R25] \*                                                                                                                32    Kidney                                                     Multicentre, UK                            Switch to mTORis                         Physical examination +/− biopsy                                    Conversion to prednisolone and sirolimus   CNI/AZA                           Cancer incidence                                 24

  Euvrard 2012[@R1] [@R64]                                                                                                             120   Kidney                                                     Multicentre, France                        Switch to mTORis                         Physical examination +/− biopsy                                    Conversion to sirolimus                    CNI                               Cancer incidence                                 24

  Hoogendijk-van den Akker 2013[@R43]                                                                                                  155   Kidney                                                     Multicentre, Netherlands, UK               Switch to mTORis                         Physical examination +/− biopsy                                    Conversion to sirolimus                    AZA/MMF/ CNI                      Cancer incidence                                 24

  Salgo 2010[@R35]                                                                                                                     44    Kidney                                                     Single centre, Germany                     Switch to mTORis                         Physical examination +/− biopsy\                                   Conversion to sirolimus and prednisone     AZA/MMF/ CNI                      Precancerous skin dysplasia incidence            12
                                                                                                                                                                                                                                                                                            Clinical photographs                                                                                                                                                                             

  **Pharmaceutical interventions -- Photodynamic therapy (n=4); oral retinoids (n=3); nicotinamide (n=1); 5% imiquimod cream (n=1)**                                                                                                                                                                                                                                                                                                                                                         

  Bavinck 1995[@R40]                                                                                                                   44    Kidney                                                     Multicentre, Netherlands                   Oral retinoid                            Physical examination +/− biopsy                                    Acitretin                                  Placebo                           Cancer incidence precancerous lesion reduction   6

  Brown 2005[@R38]                                                                                                                     21    Kidney                                                     Multicentre, UK                            Topical immune response modifier cream   Physical examination +/− biopsy Clinical mapping and photographs   5% Imiquimod cream                         Placebo                           Reduction of precancerous lesions                4

  Chen 2016[@R29] \*                                                                                                                   22    Kidney                                                     Single centre, Australia                   Nicotinamide                             Physical examination                                               Nicotinamide                               Placebo                           Cancer incidence                                 6

  de Sevaux 2003[@R26] \*                                                                                                              26    Kidney                                                     Single centre, Netherlands                 Oral retinoid                            Physical examination +/- biopsy                                    High dose acitretin                        Low dose acitretin                Cancer and precancerous incidence                12

  Dragieva 2004[@R36]                                                                                                                  17    Kidney, heart                                              Single centre, Switzerland                 Photodynamic therapy                     Physical examination +/− biopsy\                                   Methyl aminolevulinate cream               Placebo                           Precancerous lesion response                     4
                                                                                                                                                                                                                                                                                            Clinical photographs                                                                                                                                                                             

  George 2002[@R42]                                                                                                                    23    Kidney                                                     Multicentre, Australia                     Oral retinoid                            Physical examination Annual radiological evaluation                Acitretin                                  Drug-free period                  Cancer incidence                                 24

  Togsverd-Bo 2015[@R27] \*†                                                                                                           25    Kidney                                                     Single centre, Denmark                     Photodynamic therapy                     Physical examination Clinical photographs                          Methyl aminolevulinate cream               No treatment contralateral area   Actinic keratosis incidence                      36

  Togsverd-Bo 2017[@R37] †                                                                                                             35    Kidney, lung, liver                                        Multicentre, Denmark and Sweden            Photodynamic therapy                     Physical examination Questionnaire/diary                           Methyl aminolevulinate cream               5% Imiquimoid cream               Actinic keratosis lesion response                6

  Wulf 2006[@R44] †                                                                                                                    27    Kidney                                                     Multicentre, Denmark and Netherlands       Photodynamic therapy                     Clinical mapping and photographs                                   Methyl aminolevulinate cream               No treatment contralateral area   Cancer incidence                                 12
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Excluded from analyses---no meaningful data to extract.

†Randomised controlled areas of skin on individuals.

‡Excluded from analyses---same participants as Robinson 2016.

§111 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, USA), South Africa and South America (Argentina, Brazil, Chile).

AZA, azathioprine; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; mTORis, mammalian target of rapamaycin inhibitors.

Risk of bias and quality of the evidence {#s3-3}
----------------------------------------

Overall studies had either high or unclear risk of bias for at least one domain ([figure 2](#F2){ref-type="fig"}; [online supplementary figure S2](#SP1){ref-type="supplementary-material"}). Random sequence generation and allocation concealment were unclear in most studies (n=12, 60%). Blinding of participants was not done in most studies (n=16, 80%) and blinding of outcome assessors was only reported in half of the studies (n=10). Intention to treat analyses were used in 6 (30%) studies and 6 (30%) studies had a high loss to follow-up. A total of 3 (15%) studies had incomplete outcome data, and all studies were at low risk for selective reporting. Seven (35%) studies reported industry involvement in authorship, design or data analysis, and of the 16 trials requiring trial registration, only 9 (56%) reported accordingly.

![Risk of bias of included studies.](bmjopen-2019-029265f02){#F2}

The overall quality of the evidence was very low for all outcomes ([online supplementary table S1](#SP1){ref-type="supplementary-material"}) due to limitations in study design, heterogeneity in the intervention and outcome measures, the very small sample size of individual studies and the small number of studies for each specific outcome. Obtaining an overall summary estimate was difficult for many outcomes due to the variability in the analytical methods and reporting in individual studies. In particular, assessment of reporting of sun protection behaviour and sun protection knowledge was not possible as outcomes were inconsistent and there was large diversity of interventions used (eg, written education material vs a mobile app programme). Furthermore, formal testing of publication bias was not performed due to insufficient data.

Interventions {#s3-4}
-------------

The interventions in the included studies were grouped into three broad categories, behavioural (n=6), switch to mTORis (n=6) and other pharmaceutical interventions (n=9, photodynamic therapy, immune response modifiers, oral retinoids and nicotinamide). Studies of behavioural interventions used passive methods of delivery including written educational material (n=2), both written educational material and text messages (n=1), mobile app programmes (n=2) and a video (n=1).

All six studies of immunosuppression compared mTORis (sirolimus) to calcineurin inhibitors (CNIs) based therapies.

Four of the eight studies of other pharmaceutical interventions assessed the effect of photodynamic therapy using methyl aminolevinate creams compared with placebo (n=1), no treatment to contralateral area (n=2) or a topical immune response modifier cream (n=1). Three studies assessed oral retinoid using acitretin compared with placebo (n=1), lower dose (n=1) or a drug-free period (n=1), one study assessed nicotinamide compared with placebo and a single study assessed the benefits of topical immune response modifier compared with placebo in kidney transplant recipients.

Effect of behavioural interventions on sun protection outcomes {#s3-5}
--------------------------------------------------------------

### Sun protection behaviour {#s3-5-1}

Sun protection behaviour, defined as hours spent outdoors per week, use of sunscreen, wearing protective clothing and seeking shade, was assessed in three trials.[@R30] Educational workbooks,[@R30] educational workbooks and text messages[@R31] and a mobile app program[@R32] were compared with standard care. Patients who received behavioural interventions reported improved sun protection behaviour scores[@R30] (3 studies, 414 participants, SMD 0.89, 95% CI −0.84 to 2.62, I^2^ 98%, [table 3](#T3){ref-type="table"}; [figure 3](#F3){ref-type="fig"}). We are uncertain of the effects of behavioural interventions on sun protection behaviour due to very low quality of evidence. A single trial assessed a standardised and validated educational workbook and found an improvement in the proportion of participants engaging in skin self-examination after 1 month (75 participants, RR 4.14, 95% CI 2.22 to 7.72).[@R33] One trial assessed a mobile app programme and reported a reduction in daily hours spent outdoors among the intervention group (170 participants, MD −6.12, 95% CI −711 to −5.13).[@R32]

![Behaviouralinterventions---sun protection behaviour (general).](bmjopen-2019-029265f03){#F3}

###### 

Effect of behavioural interventions on sun protection outcomes

  Outcome                                                                                       Studies   Participants   Weighted MD/SMD (95% CI)   RR                     P         I^2^   Intervention                                       Comparator
  --------------------------------------------------------------------------------------------- --------- -------------- -------------------------- ---------------------- --------- ------ -------------------------------------------------- ---------------
  **Behavioural intervention (n=5**)                                                                                                                                                                                                           
  ***Sun protection behaviour***                                                                                                                                                                                                               
  General sun protection behaviour                                                              3         414            0.89 (−0.84 to 2.62)                              0.31      98%    Workbook, text messages, mobile app programme      Standard care
  Skin self-examination                                                                                                                                                                                                                        
   1 month after visit                                                                          1         75                                        4.14 (2.22 to 7.72)    \<0.001   N 0.   Workbook                                           Standard care
   If checked, concerned                                                                        1         42                                        6.43 (0.42 to 98.58)   0.18      N/A                                                       
   If concerned, saw dermatologist                                                              1         12                                        Not estimable\*                  N/A                                                       
  Decrease daily hours outdoors                                                                 1         170            −6.12 (−7.11 to −5.13)†                           \<0.001   N/A    Mobile app programme                               Standard care
  ***Sun protection knowledge***                                                                4         489            0.50 (0.12 to 0.87)                               0.01      76%    Workbook, text messages, mobile app programme      Standard care
  ***Sun protection attitude***                                                                                                                                                                                                                
  Concern about developing skin cancer                                                          3         348            1.88 (0.96 to 2.80)                               \<0.001   92%    Workbook, text messages, mobile app programme      Standard care
  Recognise personal risk                                                                       2         273            0.61 (−0.60 to 1.82)                              0.32      96%    Workbook and text messages, mobile app programme   Standard care
  Confidence in ability to perform sun protection                                               2         273            0.77 (−0.14 to 1.68)                              0.10      92%                                                       
  Willingness/intention to change behaviour                                                     2         273            1.70 (−1.68 to 5.07)                              0.32      99%                                                       
  Knowledge of significance of skin cancer, relevance of sun protection, risk of having a tan   1         101            7.00 (2.94 to 11.06)                              0.001     N/A    Workbook and text messages                         Standard care
  Confidence in ability to recognise a skin cancer                                              1         75             1.80 (1.35 to 2.25)                               \<0.001   N/A    Workbook                                           Standard care
  Importance of skin self-examination                                                           1         75             1.05 (0.61 to 1.49)                               \<0.001   N/A                                                       
  Importance of partner help for skin self-examination                                          1         75             1.59 (1.10 to 2.08)                               \<0.001   N/A                                                       
  ***Complications***                                                                                                                                                                                                                          
  Skin irritation                                                                                                                                                                                                                              
   None                                                                                         2         271                                       1.00 (0.89 to 1.13)    0.95      95%    Workbook and text messages, mobile app programme   Standard care
   \>1                                                                                          2         271                                       0.77 (0.43 to 1.36)    0.36      89%                                                       
  Sunburn (past week)                                                                                                                                                                                                                          
   None                                                                                         2         271                                       3.19 (2.47 to 4.10)    \<0.001   99%                                                       
   \>1                                                                                          2         271                                       2.68 (1.81 to 3.96)    \<0.002   95%                                                       
  ***Biologic measures***                                                                                                                                                                                                                      
  Melanin index--- RU arm (sun protected                                                        2         271            0.12 (−0.12 to 0.35)                              0.34      0%     Workbook and text messages, mobile app programme   Standard care
  Melanin index---R forearm (sun exposed)                                                       2         271            −0.42 (−0.66 to -0.18)†                           0.001     0%                                                        
  Cheek (sun exposed)                                                                           2         271            −0.25 (−0.64 to 0.15)†                            0.22      61%                                                       
  Sun damage assessment---R forearm                                                             2         271            −0.13 (−0.40 to 0.13)†                            0.33      16%                                                       

\*Unable to estimate due to absence of comparator group.

†Reduction of outcome of interest represents an improvement.

MD, mean difference; SMD, standardised mean difference.

### Sun protection knowledge {#s3-5-2}

The effectiveness of educational workbooks, text messages, mobile app programmes and videos on sun protection knowledge was assessed in six studies,[@R24] four of which provided data for a meta-analysis. There was an improvement in knowledge scores (4 studies, 489 participants, SMD 0.50, 95% CI 0.12 to 0.87, I^2^ 76%) in the intervention group compared with standard care ([figure 4](#F4){ref-type="fig"}).[@R30] One study compared an interactive visual representation of the educational programme with standard information pamphlets and found that knowledge of sun protection improved among those who received the educational video.[@R28]

![Behaviouralinterventions---sun protection knowledge.](bmjopen-2019-029265f04){#F4}

### Sun protection attitude {#s3-5-3}

Three studies assessed sun protective attitude after receiving an educational workbook, text messages or a mobile app programme over a period of 0.5 months to 1.5 months.[@R31] Compared with standard care, there was an overall improvement in scores of concern about developing cancer (3 studies, 348 participants, SMD 1.85, 95% CI 1.59 to 2.11, I^2^ 96%).[@R31] Two studies involving 273 participants reported an improvement in scores of understanding the personal risk of skin cancer (SMD 0.61, 95% CI −0.60 to 1.82, I^2^ 96%), adherence to sun protection (SMD 0.77, 95% CI −0.14 to 1.68, I^2^ 92%) and willingness or intention to change behaviour (SMD 1.70, 95% CI −1.68 to 5.07, I^2^ 99%).[@R31] We are uncertain of the effects of behavioural interventions on sun protection attitude due to very low quality of evidence. A single study involving 75 participants also reported an improvement in scores of ability to recognise a potential skin cancer (MD 1.80, 95% CI 1.35 to 2.25), importance of skin self-examination (MD 1.05, 95% CI 0.61 to 1.49) and having a partner help for skin self-examination (MD 1.59, 95% CI 1.10 to 2.08).[@R33] Another single study reported an improvement in the importance of engaging in sun protection (measured using 5-point Likert scale, 101 participants, MD 7.00, 95% CI 2.94 to 11.06).[@R31]

### Skin complications and biologic measures {#s3-5-4}

Two trials of behavioural interventions in 271 kidney transplant recipients compared a mobile app or an educational workbook and text messages to standard care on reported skin complications and biologic measures of sun exposure.[@R31] The intervention group experienced a reduced incidence of skin irritation (a culturally relevant term for sun exposure[@R34] (RR 1.00, 95% CI 0.89 to 1.13, I^2^ 95%) or sunburn (RR 3.19, 95% CI 2.47 to 4.10, I^2^ 99%). They also had a decreased melanin index (right forearm, SMD −0.42, 95% CI −0.66 to −0.18; cheek SMD −0.25, 95% CI −0.64 to −0.15) and reduced severity of sun damage (SMD −0.13, 95% CI −0.40 to 0.13) on sun exposed areas (measured using clinical images of chronic sun damage and scored 1--10).

Effect of pharmaceutical interventions on skin cancer prevention {#s3-6}
----------------------------------------------------------------

The incidence and responses of precancerous lesions were measured only in trials of pharmaceutical interventions ([table 4](#T4){ref-type="table"}). These included the switch to mTORis (n=1),[@R35] photodynamic therapy (n=2)[@R36] and immune response modifiers (n=1)[@R38] to current treatment or placebo. The incidence of NMSCs was assessed in nine pharmaceutical studies.[@R1] None included melanoma as an outcome.

###### 

Effect of pharmaceutical interventions on skin cancer prevention

  Outcome                                       Studies   Participants   Relative risk            P       I^2^   Intervention         Comparator
  --------------------------------------------- --------- -------------- ------------------------ ------- ------ -------------------- -------------------------------
  **Switch to mTORis (n=5)**                                                                                                          
  ***Precancerous lesions***                                                                                                          
  Skin dysplasia                                                                                                                      
   Any improvement                              1         32             24.35 (1.55 to 381.99)   0.02    N/A    Sirolimus            CNI
   Unchanged                                    1         32             0.85 (0.28 to 2.61)      0.78    N/A                         
   Any worsening                                1         32             0.04 (0.00 to 0.66)      0.02    N/A                         
  ***Cancerous lesions***                                                                                                             
  SCC /BCC incidence                            5         1082           0.46 (0.28 to 0.75)      0.002   72%    Sirolimus            CNI
   ≥1 SCC                                       1         53             0.64 (0.35 to 1.17)      0.15    N/A                         
   Skin cancer (excluding SCC)                  1         53             0.74 (0.49 to 1.14)      0.17    N/A                         
   Skin cancer (including SCC)                  1         53             0.85 (0.61 to 1.17)      0.32    N/A                         
   Skin cancer with BCC                         1         53             0.89 (0.45 to 1.78)      0.75    N/A                         
  **Photodynamic therapy (n=3)**                                                                                                      
  ***Precancerous lesions***                                                                                                          
  Actinic keratosis reduction (1--2 sessions)                                                                                         
   Complete response                            2         50\*           5.03 (0.14 to 176.17)    0.37    85%    MAL                  Placebo to imiquimod 5% cream
   Partial response                             1         17\*           7.00 (0.39 to 125.99)    0.19    N/A    MAL                  Placebo
   No reduction                                 1         17\*           0.09 (0.02 to 0.40)      0.002   N/A                         
  ***Cancerous lesions***                       1         26\*           0.59 (0.34 to 1.03)      0.06    N/A    MAL                  No treatment
  **Immune response modifiers (n=1)**                                                                                                 
  ***Precancerous lesions***                                                                                                          
  Reduced skin atypia                           1         14\*           3.00 (0.47 to 19.35)     0.25    N/A    Imiquimod 5% cream   Placebo
  Reduced dysplasia                             1         14\*           2.14 (0.31 to 14.65)     0.44    N/A                         
  Reduced keratoses                             1         14\*           2.14 (0.31 to 14.65)     0.44    N/A                         
  Reduced number of viral warts                 1         14\*           7.00 (0.46 to 106.10)    0.16    N/A                         
  ***Cancerous lesions***                                                                                                             
  SCC incidence                                                                                                                       
  Treated (cream vs placebo)                    1         14\*           0.09 (0.01 to 1.70)      0.11    N/A    Imiquimod 5% cream   Placebo
  Untreated (control site)                      1         14\*           0.43 (0.08 to 2.37)      0.33    N/A                         
  **Oral retinoids (n=2)**                                                                                                            
  ***Cancerous lesions***                                                                                                             
  Decreased incidence:                                                                                                                
  \>1 SCC                                       1         46\*           0.40 (0.19 to 0.85)      0.02    N/A    Acitetrin            Drug-free period
  \>1 BCC                                       1         46\*           0.50 (0.14 to 1.76)      0.28    N/A                         
  New skin cancer                               1         19\*           0.22 (0.06 to 0.90)      0.03    N/A    Acitretin            Placebo

\*Control is the contralateral or similar area of skin on the same participant.

BCC, basal cell carcinoma; CNI, calcineurin inhibitor; MAL, methyl aminolaevulinate; mTORis, mammalian target of rapamaycin inhibitors; SCC, squamous cell carcinoma.

### Topical/local interventions {#s3-6-1}

One trial of 14 participants compared an immune response modifier, 5% imiquimod cream with placebo and found a reduction in the incidence of skin dysplasia (RR 2.14, 95% CI 0.31 to 14.65), skin atypia (RR 3.00, 95% CI 0.47 to 19.35), and viral warts (RR 7.00, 95% CI 0.46 to 106.10).[@R38]

One Danish study of 26 kidney transplant recipients compared photodynamic therapy with no treatment and reported a relative reduction by approximately 40% in the incidence of NMSC on the treated area (RR 0.59, 95% CI 0.34 to 21.03, p 0.06).[@R44] A lower incidence of SCC was also reported in one trial comparing two areas of skin using an immune response modifier and placebo (14 participants, RR 0.09, 95% CI 0.0.01 to 1.70).[@R38] Two trials comparing photodynamic therapy to an immune response modifier or photodynamic therapy to placebo in recipients with diagnosed keratoses reported a complete response rate of 60% compared with 24% in the control group (50 participants, RR 5.03, 95% CI 0.14 to 176.17, I^2^ 85%).[@R36] We are uncertain of the effects of photodynamic therapy on incidence of precancerous lesions due to very low quality of evidence. Further, one trial which was not included in the meta-analysis, reported a higher cumulative incidence of actinic keratosis lesions in untreated skin (63%) compared with skin treated by photodynamic therapy (28%).[@R27]

### Systemic interventions {#s3-6-2}

mTORis therapy reduced the incidence of NMSC compared with CNIs maintenance therapy (5 trials, 1082 participants, RR 0.46, 95% CI 0.28 to 0.75, I^2^ 72%, [figure 5](#F5){ref-type="fig"}).[@R1] However, evidence was limited due to short follow-up periods, variability in dosing of mTORis and significant rates of loss to follow-up, and therefore we are uncertain of the effects of mTORis on skin cancer incidence due to very low quality of evidence. A single trial involving 21 patients reported a reduction in the overall incidence of SCC by 49% in the conversion arm, but reported a drop out rate of 77% and follow-up time of less than 2 years.[@R25] Further, a single trial which compared mTORi conversion from CNI-based therapy reported a significant improvement in skin dysplasia (32 participants, RR 24.35, 95% CI 1.55 to 381.99).[@R35]

![Switch to mTORis---NMSC incidence. BCC, basal cell carcinoma; mTORis, mammalian target of rapamaycin inhibitors; NMSC, non-melanoma skin cancer; SCC, squamous cell carcinoma.](bmjopen-2019-029265f05){#F5}

Two trials comparing an oral retinoid, acitretin, with placebo or a drug-free period reported an increased lower risk of both SCCs and BCCs (46 participants, RR 0.40, 95% CI 0.19 to 0.85, p 0.02; RR 0.50, 95% CI 0.14 to 1.76)[@R42] or development of a new skin cancer (19 participants, RR 0.22, 95% CI 0.06 to 0.90). However, there were no differences in the incidence of new SCCs.[@R40] One trial, which was not included in the meta-analysis, showed approximately a 50% reduction in the incidence of actinic keratosis which compared a high dose to a low dose of acitretin.[@R26]

One Australian trial of 22 kidney transplant recipients compared nicotinamide with placebo and reported an estimated relative rate difference of 0.35 (95% CI −0.62 to 0.74), 0.67 (95% CI −0.40 to 0.90) and 0.07 (95% CI −1.51 to 0.65) for NMSC, BCCs and SCCs respectively.[@R29]

Subgroup analysis {#s3-7}
-----------------

Study size, trial duration, setting and risk of bias did not modify the effects of CNIs and mTORis on skin cancer incidences ([online supplementary figure S3](#SP1){ref-type="supplementary-material"}). Sources of heterogeneity for other treatment effects could not be explored due to insufficient data.

Discussion {#s4}
==========

Skin cancers (both non-melanoma and melanoma) are major causes of morbidity and mortality in solid organ transplant recipients. Despite this, trials of interventions aimed at preventing skin cancer in solid organ transplant recipients are few in number (20 trials), small with half comprising of 50 patients or less, of short duration (48% have \<12 months follow-up) and 52% do not include incidence of skin cancer as an outcome. Our review included 22 reports of 20 trials involving 2295 transplant recipients, who were predominately kidney transplant recipients. The studies covered a broad range of interventions, including behavioural to improve sun protection behaviour and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence. None of the behavioural intervention studies included precancerous lesions or skin cancer incidence as outcomes. Although interventions showed plausible improvements to sun protection behaviours, precancerous lesion responses and cancer incidence, there was considerable variability across intervention types, variability in outcomes assessed and outcome estimates. Overall, the current evidence for interventions for skin cancer prevention in solid organ transplant recipients is of very low quality and is insufficient to guide decision-making and clinical practice.

Although behavioural interventions appeared to improve sun protection attitude, knowledge and behaviour, there were inconsistencies detected and none of these studies included skin cancer as an outcome. Due to limited number of studies, we were unable to compare specific behavioural interventions (eg, mobile app vs written education) to ascertain the most effective method of delivering sun protection education. While there may be some modest benefits in the reduction in cancer incidence (for NMSC) among solid organ transplant recipients who were converted to mTORis compared with those on CNI maintenance, there was substantial heterogeneity across the studies that was unable to be explained by subgroup analyses. Heterogeneity may be attributed to the absence of long-term follow-up, large discontinuation rates owing to adverse events and variability in the doses of mTORis. Pharmaceutical interventions (switch to mTORis, photodynamic therapy, immune response modifiers) showed a reduction in precancerous lesions compared with standard care or a comparator group. However, uncertainty exists in the treatment effects and there were too few studies, interventions were incomparable, follow-up times were variable and considerable loss to follow-up for some studies to conclude that the benefits are sustainable.

Previous systematic reviews have evaluated the impact of behavioural interventions on skin cancer prevention in the general population,[@R45] and concluded that computer programmes may increase sun protective behaviours, and 'appearance-focused' interventions may decrease sun tanning and UV exposure in adolescents and young women, respectively. Reviews conducted in other populations at high-risk including outdoor workers,[@R46] family history, personal history and phenotypic factors[@R47] have found similar improvement in sun protective behaviours, including use of sunscreen, as well as a decreased incidence of keratoses. A systematic review of the benefits and harms of oral retinoids for the prevention of skin cancer among high-risk transplant recipients led to inconclusive results on the effect of acitretin due to the small number of included trials.[@R48]

Despite the inclusion of all interventions aimed at the prevention of skin cancer in solid organ transplant recipients and the comprehensive systematic search for eligible studies, there are some potential limitations. Due to the heterogeneity of the studies, the high risk of bias, the potential for reporting bias and imprecision in the point estimates of individual studies, there is a high degree of uncertainty in the estimate of the effect of skin cancer prevention interventions. All studies of behavioural interventions were undertaken in USA, with four by the same authors, while most pharmacological intervention studies were conducted in Europe. There were also large discontinuation rates owing to adverse events in trials of mTORis. Further, given the small number of studies included in the meta-analysis, we were unable to perform any detailed subgroup analyses to explore heterogeneity or assess for publication bias. While we were unable to show and assess publication bias using standard statistical tests, we would suggest the observed heterogeneity may also be attributed to potential publication and reporting biases. It is difficult to quantify the extent of such bias in this review, but one would expect research with 'positive' findings that indicate an intervention works, such as behavioural interventions improve sun protection, are more likely to be published more than one, in high impact journals and more likely to be cited. Finally, few trials included patient important outcomes associated with skin cancer and none included melanoma or mortality.

The use of pharmaceutical and immunosuppression therapy remains complex. Not only has mTORi therapy shown benefits in lowering the risk of skin cancer, early conversion to mTORi therapy from CNIs has also shown promising effects in reducing cancer rates.[@R49]On the contrary, overall mortality is higher and discontinuation following adverse events is more common in patients who receive mTORi therapy.[@R49] Several RCTs showed a higher rate of patients reporting adverse events or drug discontinuation with sirolimus,[@R1] demonstrating concern of its clinical usefulness.[@R49] Nicotinamide may also offer benefits to reducing skin cancer incidence by 20% and is relatively safe with minimal side effects. The protective effect of nicotinamide on skin cancer incidence in kidney transplant recipients is currently being explored in a phase III RCT.

Although behavioural change is a simple strategy, long-term adherence remains challenging.

While behavioural counselling has been shown to increase sun protective behaviours in non-transplant populations,[@R45] there is no direct evidence to show that the behavioural change led to a reduction in morbidity and mortality. Previous studies have suggested that transplant recipients do not practice sun protective behaviours regularly,[@R51] were less likely to use sunscreen[@R54] and that patients have to perceive skin cancer as being an important risk to be motivated to change behaviour.[@R55] However, studies on risk perception of transplant recipients remain conflicting. Given this complexity and the observed inconsistencies in the existing trials, process evaluations including facilitators and barriers to behavioural change should be included in future trials. Such evaluations could include the use of qualitative methodology to support the trial design, ascertain the perspectives of participants on the intervention and evaluate the implementation.[@R57]

We suggest that further strategies for skin cancer prevention in transplant recipients require a multifaceted and individualised approach. Transplant recipients are likely to benefit from early implementation of education, particularly before transplantation occurs and recipients may be preoccupied with other health needs related to transplantation. Although recipients understand the importance of ongoing education for the ability to self-manage their disease, they may experience difficulty in concentrating and learning new knowledge, and are often unable to look beyond their graft and the anxiety/fear of graft loss.[@R59] Interventions should be integrated into routine appointments and tailored to meet the individual needs of patients. This would be best achieved through a shared decision-making approach to identify the patient's preferences and priorities and thereby enhance the likelihood of success of self-management and prevention.[@R62]

Additional large-scale and high-quality RCTs are needed to demonstrate the effectiveness of interventions used to prevent skin cancer in transplant recipients in terms of patient important outcomes, in particular morbidity and mortality associated with skin cancer. Determining patient's preferences for prevention and management of skin cancer is also warranted to ensure interventions and outcomes for trials are relevant to patient needs and priorities and better support patient-centred treatment decisions.[@R63] Evidence of the efficacy of sun protective behaviour interventions need to be strengthened, with use of measures that are homogeneous, reliable and validated.

Preventative measures including behavioural, switch to mTORis and other pharmaceuticals may improve skin cancer outcomes for solid organ transplant recipients. However, the overall quality of evidence is very low and insufficient to guide decision-making and clinical practice. Future robust studies that are well powered, have long-term follow-up and use clinical and patient important outcome measures in a consistent manner are required to therefore optimise outcomes for solid organ transplant recipients.
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